Abbott Laboratories (ABT): financials, SEC filings and peers

Abbott Laboratories (ABT) is a health care equipment company in the Health Care sector of the S&P 500, headquartered in North Chicago, Illinois.

It was founded in 1888 and joined the S&P 500 on March 4, 1957.

Its fiscal year ends in December, and its shares trade on the NYSE.

In its SEC filings it is classified as “Pharmaceutical Preparations”.

Abbott Laboratories at a glance

Revenue (12 months): $45.1B
Revenue growth: +6.6%
Operating margin: 17.1%
Net income (12 months): $6.3B
Free cash flow (12 months): $7.4B
Cash: $6.8B
Debt: $12.9B
Diluted EPS (12 months): $3.58

Twelve months to March 31, 2026, from the 10-Q filed April 29, 2026.

Latest twelve months

Over the twelve months to March 31, 2026, Abbott Laboratories reported revenue of $45.1 billion, about the same as a year earlier (+6.6%).

Its operating margin was 17.1%: for every $100 of sales, about $17 was left as operating profit.

Net income was $6.3 billion (13.9% of revenue), 53.5% lower than a year earlier.

Profit fell while sales grew, which usually points to higher costs, heavier investment or one-time items. The filings explain which.

Operating cash flow was $9.5 billion and capital spending $2.1 billion, leaving free cash flow of $7.4 billion (16.3% of revenue).

At the end of the period it held $6.8 billion in cash and $12.9 billion in debt, a net debt position of $6.1 billion.

Five-year trend

Revenue went from $34.6 billion in fiscal 2020 to $44.3 billion in fiscal 2025, about 5.1% a year.
Operating margin widened from 15.5% to 18.2% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$43.1B	$43.7B	$40.1B	$42.0B	$44.3B
Revenue growth	24.5%	1.3%	-8.1%	4.6%	5.7%
Operating margin	19.6%	19.2%	16.2%	16.3%	18.2%
Net income	$7.1B	$6.9B	$5.7B	$13.4B	$6.5B
Free cash flow	$8.6B	$7.8B	$5.1B	$6.4B	$7.4B
Diluted EPS	$3.94	$3.91	$3.26	$7.64	$3.72

Fiscal years as reported in Abbott Laboratories’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

8-K filed August 20, 2026 — Regulation FD disclosure; Other event
10-Q filed July 28, 2026 — quarterly report
8-K filed July 16, 2026 — Earnings results
10-Q filed April 29, 2026 — quarterly report
8-K filed April 27, 2026 — Executive or director change; Bylaw or fiscal-year change
8-K filed April 17, 2026 — Other event
8-K filed April 16, 2026 — Earnings results
8-K filed March 23, 2026 — Other event

All Abbott Laboratories filings on SEC EDGAR

Companies like Abbott Laboratories

Other S&P 500 companies in Health Care Equipment:

More from Health Care

All 60 Health Care companies →

Questions about Abbott Laboratories

Is Abbott Laboratories's revenue growing?

Yes. Revenue for the twelve months to March 31, 2026 was $45.1 billion, up 6.6% from a year earlier, according to its SEC filings.

Is Abbott Laboratories profitable?

Yes. It earned $6.3 billion in net income over the twelve months to March 31, 2026, a net margin of 13.9%.

Does Abbott Laboratories have more cash or more debt?

At March 31, 2026 it had $6.8 billion in cash and $12.9 billion in debt, so more debt than cash.

When did Abbott Laboratories last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on July 28, 2026.

Which companies are similar to Abbott Laboratories?

In the S&P 500, Abbott Laboratories is grouped in Health Care Equipment within the Health Care sector. Baxter International (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Dexcom (DXCM), Edwards Lifesciences (EW) are in the same group.

Understand the numbers

Source: Abbott Laboratories’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.